Our study further confirmed that this strategy targeting site-specific O-GlcNAcylation on Bmal1 in hippocampal neurons may serve as a novel therapeutic approach for the treatment of cognitive impairment in diabetes. This evidence concerns the gene BMAL1 and Cognitive impairment.